Patient-Derived Scaffolds as a Drug-Testing Platform for Endocrine Therapies in Breast Cancer

A patient-derived scaffold model was evaluated as a testing platform for the endocrine therapies (Z)-4-Hydroxytamoxifen and fulvestrant as well as the CDK4/6-inhibitor palbociclib, monitoring the treatment responses in breast cancer cell lines MCF7 and T47D adapted to the patient-based microenvironments.